CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Cue Biopharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$16.08−0.63 (-3.77%)
Close on Oct 19, 2026
- Market cap
- $101.96M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
22.6%
2M of 7M shares
Institutional holders
49
48 new, 1 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
5 buys · 11 sales
Net sold $1.94M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mark E. Strome | 644,916 | 8.50% | 13G (passive) amendment | Jul 14, 2026 |
| Bleichroeder Holdings LLC | 6,127,662 | 9.99% | 13G (passive) amendment | Mar 19, 2025 |
| Bleichroeder LP | 6,127,662 | 9.99% | 13G (passive) amendment | Sep 30, 2024 |
| Shao-Lee Lin | 467,166 | 6.20% | 13D (active) | May 3, 2026 |
| Driehaus Capital Management LLC | 292,144 | 6.96% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CUE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bleichroeder LP | 370,682 | 5.10% | $11.70M | New | 2.09% |
| Driehaus Capital Management LLC | 292,144 | 4.02% | $9.22M | New | 0.05% |
| Vanguard Capital Management LLC | 161,700 | 2.23% | $5.10M | New | 0.00% |
| Ikarian Capital, LLC | 104,364 | 1.44% | $3.29M | New | 0.35% |
| TFG Asset Management GP Ltd | 93,819 | 1.29% | $2.96M | New | 0.47% |
| Stempoint Capital LP | 66,995 | 0.92% | $2.11M | New | 0.36% |
| BlackRock, Inc. | 57,807 | 0.80% | $1.82M | New | 0.00% |
| ADAR1 Capital Management, LLC | 55,193 | 0.76% | $1.74M | New | 0.08% |
| Lion Point Capital, LP | 52,928 | 0.73% | $1.67M | New | 7.99% |
| Squadron Capital Management LLC | 50,000 | 0.69% | $1.58M | New | 0.49% |
| Diadema Partners LP | 48,369 | 0.67% | $1.53M | New | 0.19% |
| Geode Capital Management, LLC | 47,824 | 0.66% | $1.51M | New | 0.00% |
| Boothbay Fund Management, LLC | 31,459 | 0.43% | $992.85K | New | 0.01% |
| UBS Group AG | 26,700 | 0.37% | $842.65K | New | 0.00% |
| Citadel Advisors LLC | 25,633 | 0.35% | $808.98K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 24,476 | 0.34% | $772.46K | New | 0.00% |
| Texas Capital Bank Wealth Management Services Inc | 22,881 | 0.31% | $722.12K | New | 0.04% |
| Renaissance Technologies LLC | 14,689 | 0.20% | $463.59K | New | 0.00% |
| Persistent Asset Partners Ltd | 12,332 | 0.17% | $389.20K | New | 0.12% |
| Robertson Stephens Wealth Management, LLC | 11,133 | 0.15% | $351.36K | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 49 | 2M | 22.6% | 48 / 0 | 1 / 1 | 2M | 0M |
| Q1 2026 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CUE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 111,867 | 1.54% | $3.53M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 47,090 | 0.65% | $1.49M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 16,031 | 0.22% | $351.08K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 11,129 | 0.15% | $351.23K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 5,783 | 0.08% | $126.65K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 4,812 | 0.07% | $105.38K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 1,815 | 0.02% | $48.71K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 1,724 | 0.02% | $54.41K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 1,019 | 0.01% | $32.16K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 975 | 0.01% | $21.35K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 747 | 0.01% | $23.58K | 0.01% | Jun 30, 2026 |
| Avantis U.S. Small Cap Equity ETF | 300 | 0.00% | $6.57K | 0.00% | May 31, 2026 |
| Dimensional US Core Equity Market ETF | 116 | 0.00% | $3.11K | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 105 | 0.00% | $2.82K | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 59 | 0.00% | $1.86K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shao-Lee Lin | Chief Executive Officer, Director | 716,455 | 9.86% | Aug 14, 2026 |
| Usman Azam | CHIEF EXECUTIVE OFFICER, Director | – | – | Oct 2, 2025 |
| Daniel R. Passeri | CHIEF EXECUTIVE OFFICER, Director | 164,578 | 2.27% | Mar 25, 2025 |
| Sumita Ray | Chief Legal Compliance Officer | 118,545 | 1.63% | Aug 17, 2026 |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer | 53,070 | 0.73% | Aug 17, 2026 |
| James M. Ahlers | Chief Financial Officer | 25,500 | 0.35% | Aug 3, 2026 |
| Dominique Christian Borie | Chief Medical Officer | 31,500 | 0.43% | Jul 15, 2026 |
| Lucinda Warren | CHIEF BUSINESS OFFICER | – | – | Apr 10, 2026 |
| Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | – | – | Apr 10, 2026 |
| Colin Sandercock | SVP, GENERAL COUNSEL | 30,499 | 0.42% | Apr 10, 2026 |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | 14,311 | 0.20% | Mar 25, 2025 |
| Matteo Levisetti | Chief Medical Officer | 9,230 | 0.13% | Mar 25, 2025 |
| Pamela Garzone | Director | 18,900 | 0.26% | Aug 28, 2026 |
| Pasha Sarraf | Director | 29,195 | 0.40% | Aug 28, 2026 |
| Daniel A. Camardo | Director | 21,800 | 0.30% | Jul 10, 2026 |
| Viola Mong Meehan | Director | 21,800 | 0.30% | Jul 10, 2026 |
| Frank Morich | Director | 28,000 | 0.39% | Jan 6, 2026 |
| Patrick Verheyen | Director | 8,174 | 0.11% | Jan 6, 2026 |
| Peter A. Kiener | Director | 357 | 0.00% | Jan 6, 2026 |
| Jill Marie Broadfoot | Director | – | – | Jan 6, 2026 |
| Frederick W. Driscoll | Director | 0 | – | Jan 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Sale | −4 | $31.13 | $125 | 118,545 |
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Sale | −6,442 | $30.35 | $195.51K | 118,549 |
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Option exercise | +18,196 | – | – | 127,374 |
| Sumita Ray Chief Legal Compliance Officer | Aug 13, 2026 | Sale | −2,383 | $29.37 | $69.99K | 124,991 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Sale | −1,519 | $29.37 | $44.61K | 53,070 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Sale | −4,106 | $30.35 | $124.62K | 48,964 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Sale | −3 | $31.13 | $93 | 48,961 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Aug 13, 2026 | Option exercise | +13,647 | – | – | 54,589 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 13, 2026 | Sale | −2,375 | $28.11 | $66.76K | 716,455 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 13, 2026 | Sale | −10,460 | $29.48 | $308.36K | 705,995 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 13, 2026 | Sale | −5,423 | $27.19 | $147.45K | 718,830 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale | −5,775 | $27.75 | $160.26K | 724,253 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 12, 2026 | Option exercise | +109,179 | – | – | 764,253 |
| Shao-Lee Lin Chief Executive Officer, Director | Aug 12, 2026 | Sale | −34,225 | $26.99 | $923.73K | 730,028 |
| James M. Ahlers Chief Financial Officer | Jul 30, 2026 | Award | +25,500 | – | – | 25,500 |
| Dominique Christian Borie Chief Medical Officer | Jul 13, 2026 | Award | +31,500 | – | – | 31,500 |
| Pasha Sarraf Director | Jul 9, 2026 | Award | +18,400 | – | – | 29,195 |
| Pamela Garzone Director | Jul 9, 2026 | Award | +18,900 | – | – | 18,900 |
| Pasha Sarraf Director | Jul 9, 2026 | Award | +21,800 | – | – | 32,595 |
| Sumita Ray Chief Legal Compliance Officer | Jul 9, 2026 | Award | +54,589 | – | – | 109,178 |
| Shao-Lee Lin Chief Executive Officer, Director | Jul 9, 2026 | Award | +327,537 | – | – | 655,074 |
| Daniel A. Camardo Director | Jul 9, 2026 | Award | +21,800 | – | – | 21,800 |
| Michael Vincent Meluzio VP, Prin. Accounting Officer | Jul 9, 2026 | Award | +40,942 | – | – | 40,942 |
| Viola Mong Meehan Director | Jul 9, 2026 | Award | +21,800 | – | – | 21,800 |
| Pamela Garzone Director | Jul 9, 2026 | Award | +21,800 | – | – | 21,800 |
| Shao-Lee Lin CHIEF EXECUTIVE OFFICER, Director | May 3, 2026 | Award | +327,537 | – | – | 327,537 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +78,116 | $0.31 | $24.22K | 246,440 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +4,229 | $0.31 | $1.31K | 4,229 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +77,148 | $0.30 | $23.14K | 81,377 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +86,947 | $0.32 | $27.82K | 168,324 |
| Pasha Sarraf Director | Dec 30, 2025 | Buy | +77,417 | $0.30 | $23.23K | 323,857 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Buy | +30,000 | $1.03 | $30.90K | 164,578 |
| Anish Suri PRESIDENT AND CSO | Aug 25, 2023 | Buy | +4,000 | $2.76 | $11.04K | 135,638 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Aug 14, 2023 | Buy | +3,000 | $2.86 | $8.58K | 134,578 |
| Peter A. Kiener Director | Mar 23, 2023 | Sale | −9,325 | $3.28 | $30.59K | 357 |
| Peter A. Kiener Director | Mar 23, 2023 | Option exercise | +9,682 | $2.86 | $27.69K | 9,682 |
| Kerri-Ann Millar CHIEF FINANCIAL OFFICER | Aug 22, 2022 | Tax withholding | −2,828 | $3.05 | $8.63K | 14,311 |
| Kerri-Ann Millar CHIEF FINANCIAL OFFICER | Aug 21, 2022 | Option exercise | +6,667 | – | – | 17,139 |
| Cameron Gray Director | Jun 14, 2022 | Tax withholding | −51,562 | $3.20 | $165.00K | 687,049 |
| Cameron Gray Director | Jun 14, 2022 | Option exercise | +61,111 | $2.70 | $165.00K | 738,611 |
| Frank Morich Director | May 27, 2022 | Buy | +28,000 | $3.75 | $105.00K | 28,000 |
| Aaron G.L. Fletcher Director | May 24, 2022 | Buy | +55,000 | $3.34 | $183.70K | 940,000 |
| Aaron G.L. Fletcher Director | May 23, 2022 | Buy | +150,000 | $3.52 | $528.00K | 885,000 |
| Aaron G.L. Fletcher Director | Mar 31, 2022 | Buy | +735,000 | $4.76 | $3.50M | 735,000 |
| Anish Suri PRESIDENT AND CSO | Mar 31, 2022 | Option exercise | +16,668 | – | – | 110,706 |
| Anish Suri PRESIDENT AND CSO | Mar 31, 2022 | Tax withholding | −7,068 | $4.88 | $34.49K | 103,638 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Mar 31, 2022 | Option exercise | +75,000 | – | – | 173,700 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Mar 31, 2022 | Gift | −10,000 | – | – | 131,578 |
| Daniel R. Passeri CHIEF EXECUTIVE OFFICER, Director | Mar 31, 2022 | Tax withholding | −32,122 | $4.88 | $156.76K | 141,578 |
| Peter A. Kiener Director | Nov 16, 2021 | Option exercise | +1,361 | $2.86 | $3.89K | 1,361 |
| Peter A. Kiener Director | Nov 16, 2021 | Sale(10b5-1 plan) | −1,361 | $18.02 | $24.53K | 0 |
| Peter A. Kiener Director | Nov 15, 2021 | Sale(10b5-1 plan) | −18,815 | $17.92 | $337.16K | 0 |
| Peter A. Kiener Director | Nov 15, 2021 | Option exercise | +18,815 | $2.86 | $53.81K | 18,815 |
| Anish Suri President and CSO | Nov 15, 2021 | Option exercise | +8,000 | $8.26 | $66.08K | 102,038 |
| Anish Suri President and CSO | Nov 15, 2021 | Sale(10b5-1 plan) | −8,000 | $18.05 | $144.40K | 94,038 |
| Anish Suri President and CSO | Nov 11, 2021 | Option exercise | +20,000 | $6.42 | $128.40K | 114,038 |
| Anish Suri President and CSO | Nov 11, 2021 | Sale(10b5-1 plan) | −20,000 | $15.07 | $301.40K | 94,038 |
| Anish Suri PRESIDENT AND CSO | Oct 6, 2021 | Tax withholding | −14,134 | $12.97 | $183.32K | 94,038 |
| Anish Suri PRESIDENT AND CSO | Oct 3, 2021 | Option exercise | +33,334 | – | – | 108,172 |
| Kerri-Ann Millar CHIEF FINANCIAL OFFICER | Oct 1, 2021 | Sale(10b5-1 plan) | −1,251 | $14.21 | $17.78K | 10,472 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lin Shao-Lee Officer, Director | Oct 13, 2026 | 11,087 | $305.49K | Oct 12, 2026 | Restricted Stock Units vesting under registered plan |
| Ray Sumita Officer, CORPORATE SECRETARY | Oct 13, 2026 | 1,844 | $51.72K | Oct 12, 2026 | Restricted Stock Units vesting under registered plan |
| Lin Shao-Lee Officer, Director | Aug 14, 2026 | 58,258 | $1.60M | Aug 12, 2026 | Restricted Stock Units vesting under registered plan |
| Ray Sumita Officer, CORPORATE SECRETARY | Aug 13, 2026 | 8,829 | $266.11K | Aug 13, 2026 | Restricted Stock Units vesting under registered plan |
| Giacomo Levisetti Matteo Officer | Dec 29, 2025 | 7,230 | $1.91K | Dec 29, 2025 | Open Market Purchase |